Symbols

TLSI

TriSalus Life·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TLSI

Trisalus Life Sciences, Inc.

An immunotherapy company that develops and commercialises therapies using a three-pronged therapeutic approach combining immunomodulation therapy, tumour-killing agents, and a proprietary intravascular regional delivery technology for the treatment of liver and pancreatic tumours

Industry

Life Science Tools and Services

Established Date

Listing Date

02/08/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

102

Fiscal Year Ends

12-31

Website

www.trisaluslifesci.com

Security Type

Common stock

Office address

6272 W. 91st Ave. , Westminster, CO 80031

Business

Introduction

TriSalus Life Sciences, Inc., was incorporated in Delaware in September 2020. The company is an oncology-focused medical technology company that combines its stress-enhancing drug delivery technology with standard therapies and an investigational immunotherapy drug designed to improve the prognosis of patients with solid tumors. Its FDA-approved TriNav infusion system is designed to enhance the delivery of endovascular therapeutic drugs by regulating intravascular pressure and flow.

Company Financials

EPS

TLSI has released its 2025 Q4 earnings. EPS was reported at -0.21, versus the expected -0.14, missing expectations. The chart below visualizes how TLSI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TLSI has released its 2025 Q4 earnings report, with revenue of 13.21M, reflecting a YoY change of 59.85%, and net profit of -9.75M, showing a YoY change of 3.51%. The Sankey diagram below clearly presents TLSI's revenue sources and cost distribution.